Megakaryoblastic transformation of polycythemia vera with hypercalcemia.
Polycythemia vera (PV) is known to occasionally transform into acute leukemia. Administration of alkylating agents seems to be associated with an increased risk of leukemic transformation of PV. Hypercalcemia is a serious complication of malignancies, but it is uncommon in acute leukemia. In the majority of malignancies with hypercalcemia, elevated parathyroid hormone-related protein (PTHrP) is thought to be the main cause of hypercalcemia. We report a rare case of megakaryoblastic transformation of PV with hypercalcemia. A 62-year-old man was diagnosed as having PV in 1983, and he had received ranimustine and busulfan. He developed acute megakaryoblastic leukemia 17 years after the initial diagnosis of PV. Serum calcium was elevated, the serum level of intact parathyroid hormone (PTH) was suppressed, and the level of intact PTHrP was slightly elevated. He had no lytic bone lesions; however, uncoupling of bone turnover due to an increase in bone resorption and a decrease in bone formation was detected by using biochemical markers. Since the level of PTHrP was slightly elevated from the normal value, we speculated that PTHrP produced in the local field by leukemic cells might have been more abundant than circulating PTHrP. Pamidronate and adrenocortical hormone were effective in reducing the serum calcium level. However, the patient died shortly after the start of induction chemotherapy. The prognosis of cases of PV that has transformed into acute leukemia is generally poor because the majority of such cases are refractory to chemotherapy.
Kurosawa
M
M
Department of Internal Medicine, Sapporo Kosei Hospital, Kita-3, Higashi-8, Chuo-ku, Sapporo 060-0033, Japan. mikurosawa5211@ ima.me-h.ne.jp
Iwasaki
H
H
D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage; D001862:Bone Resorption / Q000175:diagnosis / Q000209:etiology; D002066:Busulfan / Q000008:administration & dosage; D002118:Calcium / Q000097:blood; D002471:Cell Transformation, Neoplastic; D004164:Diphosphonates / Q000008:administration & dosage; D017809:Fatal Outcome; D006801:Humans; D006934:Hypercalcemia / Q000150:complications* / Q000188:drug therapy; D007947:Leukemia, Megakaryoblastic, Acute / Q000097:blood / Q000150:complications* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D000077268:Pamidronate; D010281:Parathyroid Hormone / Q000097:blood; D044162:Parathyroid Hormone-Related Protein; D010446:Peptide Fragments / Q000097:blood; D011087:Polycythemia Vera / Q000188:drug therapy / Q000473:pathology*; D011506:Proteins
D004164:Diphosphonates; D009607:Nitrosourea Compounds; D010281:Parathyroid Hormone; D044162:Parathyroid Hormone-Related Protein; D010446:Peptide Fragments; D011506:Proteins; C054296:parathyroid hormone-related protein (1-34); D000324:Adrenocorticotropic Hormone; D002066:Busulfan; D000077268:Pamidronate; C020766:ranimustine; D002118:Calcium